These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

204 related articles for article (PubMed ID: 29356692)

  • 1. Antitumor effects of histone deacetylase inhibitor suberoylanilide hydroxamic acid in epidermal growth factor receptor-mutant non-small-cell lung cancer lines in vitro and in vivo.
    Wei Y; Zhou F; Lin Z; Shi L; Huang A; Liu T; Yu D; Wu G
    Anticancer Drugs; 2018 Mar; 29(3):262-270. PubMed ID: 29356692
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Combined inhibition of EZH2 and histone deacetylases as a potential epigenetic therapy for non-small-cell lung cancer cells.
    Takashina T; Kinoshita I; Kikuchi J; Shimizu Y; Sakakibara-Konishi J; Oizumi S; Nishimura M; Dosaka-Akita H
    Cancer Sci; 2016 Jul; 107(7):955-62. PubMed ID: 27116120
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Anticancer activity of SAHA, a potent histone deacetylase inhibitor, in NCI-H460 human large-cell lung carcinoma cells in vitro and in vivo.
    Zhao Y; Yu D; Wu H; Liu H; Zhou H; Gu R; Zhang R; Zhang S; Wu G
    Int J Oncol; 2014 Feb; 44(2):451-8. PubMed ID: 24297449
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Novel histone deacetylase inhibitors derived from Magnolia officinalis significantly enhance TRAIL-induced apoptosis in non-small cell lung cancer.
    Liu Y; Tong Y; Yang X; Li F; Zheng L; Liu W; Wu J; Ou R; Zhang G; Hu M; Liu Z; Lu L
    Pharmacol Res; 2016 Sep; 111():113-125. PubMed ID: 27268146
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The combination of irreversible EGFR TKIs and SAHA induces apoptosis and autophagy-mediated cell death to overcome acquired resistance in EGFR T790M-mutated lung cancer.
    Lee TG; Jeong EH; Kim SY; Kim HR; Kim CH
    Int J Cancer; 2015 Jun; 136(11):2717-29. PubMed ID: 25382705
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Histone deacetylase inhibitor, suberoylanilide hydroxamic acid (SAHA), enhances anti-tumor effects of the poly (ADP-ribose) polymerase (PARP) inhibitor olaparib in triple-negative breast cancer cells.
    Min A; Im SA; Kim DK; Song SH; Kim HJ; Lee KH; Kim TY; Han SW; Oh DY; Kim TY; O'Connor MJ; Bang YJ
    Breast Cancer Res; 2015 Mar; 17():33. PubMed ID: 25888415
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A novel histone deacetylase inhibitor exhibits antitumor activity via apoptosis induction, F-actin disruption and gene acetylation in lung cancer.
    Tang YA; Wen WL; Chang JW; Wei TT; Tan YH; Salunke S; Chen CT; Chen CS; Wang YC
    PLoS One; 2010 Sep; 5(9):e12417. PubMed ID: 20856855
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Suberoylanilide hydroxamic acid increases anti-cancer effect of tumor necrosis factor-α through up-regulation of TNF receptor 1 in lung cancer cells.
    You BR; Han BR; Park WH
    Oncotarget; 2017 Mar; 8(11):17726-17737. PubMed ID: 28099148
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Suberoylanilide hydroxamic acid (Zolinza/vorinostat) sensitizes TRAIL-resistant breast cancer cells orthotopically implanted in BALB/c nude mice.
    Shankar S; Davis R; Singh KP; Kurzrock R; Ross DD; Srivastava RK
    Mol Cancer Ther; 2009 Jun; 8(6):1596-605. PubMed ID: 19509267
    [TBL] [Abstract][Full Text] [Related]  

  • 10. EGFR-TKI resistance due to BIM polymorphism can be circumvented in combination with HDAC inhibition.
    Nakagawa T; Takeuchi S; Yamada T; Ebi H; Sano T; Nanjo S; Ishikawa D; Sato M; Hasegawa Y; Sekido Y; Yano S
    Cancer Res; 2013 Apr; 73(8):2428-34. PubMed ID: 23382048
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The histone deacetylase inhibitor suberoylanilide hydroxamic acid induces growth inhibition and enhances taxol-induced cell death in breast cancer.
    Shi YK; Li ZH; Han XQ; Yi JH; Wang ZH; Hou JL; Feng CR; Fang QH; Wang HH; Zhang PF; Wang FS; Shen J; Wang P
    Cancer Chemother Pharmacol; 2010 Nov; 66(6):1131-40. PubMed ID: 20838997
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A histone deacetylase inhibitor enhances expression of genes inhibiting Wnt pathway and augments activity of DNA demethylation reagent against nonsmall-cell lung cancer.
    Shieh JM; Tang YA; Hu FH; Huang WJ; Wang YJ; Jen J; Liao SY; Lu YH; Yeh YL; Wang TW; Lin P; Wang YC
    Int J Cancer; 2017 May; 140(10):2375-2386. PubMed ID: 28233309
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antitumor effects of a novel phenylbutyrate-based histone deacetylase inhibitor, (S)-HDAC-42, in prostate cancer.
    Kulp SK; Chen CS; Wang DS; Chen CY; Chen CS
    Clin Cancer Res; 2006 Sep; 12(17):5199-206. PubMed ID: 16951239
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inhibition of class I histone deacetylases in non-small cell lung cancer by honokiol leads to suppression of cancer cell growth and induction of cell death in vitro and in vivo.
    Singh T; Prasad R; Katiyar SK
    Epigenetics; 2013 Jan; 8(1):54-65. PubMed ID: 23221619
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Anticancer effects of suberoylanilide hydroxamic acid in esophageal squamous cancer cells in vitro and in vivo.
    Tzao C; Jin JS; Chen BH; Chung HY; Chang CC; Hsu TY; Sun GH
    Dis Esophagus; 2014; 27(7):693-702. PubMed ID: 24033428
    [TBL] [Abstract][Full Text] [Related]  

  • 16. SAHA, a HDAC inhibitor, has profound anti-growth activity against non-small cell lung cancer cells.
    Komatsu N; Kawamata N; Takeuchi S; Yin D; Chien W; Miller CW; Koeffler HP
    Oncol Rep; 2006 Jan; 15(1):187-91. PubMed ID: 16328054
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Enhancement of tumor initiation and expression of KCNMA1, MORF4L2 and ASPM genes in the adenocarcinoma of lung xenograft after vorinostat treatment.
    Kuo WY; Wu CY; Hwu L; Lee JS; Tsai CH; Lin KP; Wang HE; Chou TY; Tsai CM; Gelovani J; Liu RS
    Oncotarget; 2015 Apr; 6(11):8663-75. PubMed ID: 25796627
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Histone deacetylase inhibitors suppress the growth of human osteosarcomas in vitro and in vivo.
    Wu Z; Ma C; Shan Z; Ju Y; Li S; Zhao Q
    J BUON; 2013; 18(4):1032-7. PubMed ID: 24344034
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Histone Deacetylase (HDAC) Inhibitor, Suberoylanilide Hydroxamic Acid (SAHA), Induces Apoptosis in Prostate Cancer Cell Lines via the Akt/FOXO3a Signaling Pathway.
    Shi XY; Ding W; Li TQ; Zhang YX; Zhao SC
    Med Sci Monit; 2017 Dec; 23():5793-5802. PubMed ID: 29211704
    [TBL] [Abstract][Full Text] [Related]  

  • 20. MGCD0103, a novel isotype-selective histone deacetylase inhibitor, has broad spectrum antitumor activity in vitro and in vivo.
    Fournel M; Bonfils C; Hou Y; Yan PT; Trachy-Bourget MC; Kalita A; Liu J; Lu AH; Zhou NZ; Robert MF; Gillespie J; Wang JJ; Ste-Croix H; Rahil J; Lefebvre S; Moradei O; Delorme D; Macleod AR; Besterman JM; Li Z
    Mol Cancer Ther; 2008 Apr; 7(4):759-68. PubMed ID: 18413790
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.